Recent studies have demonstrated a promising benefit of chemotherapy and immunotherapy (trastuzumab) combination regimens in a neoadjuvant setting in patients with HER-2 amplification breast cancer [28,29]. The gene discussed is ERBB2; the disease is breast carcinoma.